Latest Contrast Nephropathy News
N-acetylcysteine patients had significantly decreased odds of contrast-induced nephropathy.
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.
Greatest reduction for N-acetylcysteine in patients receiving low-osmolar contrast media.
Risk is linked to small changes in serum creatinine and eGFR on the day after contrast exposure.
Reduced risk of contrast-induced nephropathy with no increase in acute heart failure.
Study reveals a 13% incidence of CIN in allograft recipients undergoing computed tomography or cardiac catheterization with contrast media.
Contrast-Induced Nephropathy is significantly associated with mortality and need for dialysis; hydration is also a predictor of CIN.
Increased long-term mortality risk for patients with, but not those without, chronic kidney disease.
Researchers found no statistically significant incidence of CIN in a study of 2,277 patients who had a total of 2,583 CT scans with contrast.
In a study of patients undergoing coronary procedures, the incidence of CIN was 2.7% alprostadl recipients versus 11.1% of controls.
The condition was 67% less likely to develop in patients who received a nitrate before percutaneous coronary intervention.
It might decrease the likelihood of renal function decline, however.
Contrast volume:eGFR ratio may be useful in calculating the maximum amount of contrast to give.
Use of ACE inhibitors and angiotensin receptor blockers during coronary angiography found to independently boost risk by 43%.
PRAGUE—Transient hyponatremia may precede development of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography, according to investigators.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)